Aegis Unveils Discoverant 4.0 Enterprise Manufacturing Intelligence Software

Latest Version Leverages Microsoft SharePoint for Improved Global Collaboration

LAFAYETTE, Colo.--(BUSINESS WIRE)-- Aegis Analytical Corp., the leading provider of Enterprise Manufacturing and Process Intelligence software, announced today the availability of Aegis Discoverant® 4.0, the latest version of its global software platform.

Discoverant is used by global process manufacturers – including Abbott, Baxter, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genzyme, Human Genome Sciences, Merck Serono and others – for improved process predictability, quality and yield and to help them achieve operational excellence through on-demand and scheduled access to all manufacturing, quality and process development data.

Discoverant 4.0 includes the integration of powerful tools for data access and sharing across multiple manufacturing sites and contract manufacturing organizations (CMOs), enabling better collaboration and real-time decision making.

The new version leverages Microsoft SharePoint Web Parts to provide high level reports designed specifically for observational users without the detailed functionality that Discoverant investigational users require.

Additional Discoverant 4.0 benefits include:

  • Direct Connect Manager which provides a “data-gathering engine” to power Discoverant’s new enterprise server functionality and connect users to data sources across geographies.
  • Enhanced multi-phase analysis (MPA) capabilities to examine chromatography, fermentation and other multi-phase data. Customers use MPA, for example, to help minimize the risk of impurities entering the product stream.
  • Improved performance for large analysis groups (AGs). AGs contain the data gathered using Aegis’ patented methodology for mapping data from multiple database sources.
  • Improved KnowledgeNet, with a browser-based manager and viewer, allows exposure of Discoverant output via a Uniform Resource Locator (URL).
  • Enhanced functionality/performance for Aegis’ Hierarchy Verification Utility (HVU) tool used to link and aggregate continuous data sources.

Discoverant 4.0 was built to help customers expand to multi-site, multi-national manufacturing environments,” said Aegis President and CEO Robert Di Scipio. “Discoverant 4.0 not only makes data aggregation and analysis easier, it also simplifies internal and external data sharing.”

Current Aegis customers can contact their account managers for information on upgrades.

  • To download a demonstration of Discoverant for Pharma – Click Here
  • To download a demonstration of Discoverant for Biotech – Click Here

ABOUT AEGIS

Aegis Analytical Corp. provides Discoverant software, an Enterprise Manufacturing Intelligence platform that enables manufacturers to produce regulated and specialty products more efficiently. Discoverant software leverages existing IT investments and provides on-demand access, contextualization, analysis and reporting for all manufacturing, quality and process development data. Aegis’ customers achieve operational excellence through improved process performance and understanding, lower cost of compliance, accelerated tech transfer and process scale-up and predictability in lean supply chains. Unlike many business intelligence offerings, Aegis’ Discoverant software enables process intelligence, which provides a deeper understanding of each process and product. To learn more, visit: www.aegiscorp.com. Follow Aegis on Twitter at: @discoverant.

Aegis and Discoverant are registered trademarks of Aegis Analytical Corp. Other names may be trademarks of their respective owners.



CONTACT:

Aegis Analytical Corp.
Media Contact:

Mary Biermann, 303-625-2130
Director of Marketing
[email protected]
or
Customer Inquiries:
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Technology  Data Management  Hardware  Software  Other Technology  Health  Biotechnology  Pharmaceutical  Manufacturing  Chemicals/Plastics  Other Manufacturing  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.